S2E18: Early Cancer Detection, Reimagined. Don't Be Dense, Get Checked with Liz Cormier-May, CEO of Mammogen

25 October 2024

Did you know that mammograms have remained virtually unchanged since their invention in 1913? It's no wonder they feel archaic!

Welloff Podcast promo: Season 2 Episode 18, “Early Cancer Detection, Reimagined,” with two hosts and guest Liz Cormier-May

In honor of Breast Cancer Awareness Month, Dr. Tara and Gina Simm welcome Liz Cormier-May, CEO of Mammogen, to the iHeartRadio studio. As a chemist and leader in the field, Liz is driving innovation in breast cancer detection, making it early, affordable, and accessible.


And here's the exciting part: a simple blood test for breast cancer detection could be available as early as next year! 


Tune in to find out how this groundbreaking development will change the game in cancer detection, what the categories are for dense breasts AND what the heck a Bi-Rads category is!


Mammogen is currently accepting patients for their clinical trial. Please visit mammogen.bio to sign up!


Listen to the full episode here:

https://www.buzzsprout.com/2307750/episodes/15954302

Mammogen Names National Cancer Screening Leader, Dr. Rebecca Kaltman, to Lead Pivotal genTRU-breast™ Study

20 October 2026
BioSpace | October 20, 2026 Mammogen announced the appointment of Rebecca D. Kaltman, M.D., Executive Director of the Inova Saville Cancer Screening and Prevention Center, as Principal Investigator for its KATELYN-ERIN clinical trial. The study will evaluate genTRU-breast™, Mammogen's RNA-powered blood-based assay being developed to support earlier breast cancer detection, particularly for women with dense breast tissue. Dr. Kaltman brings 20 years of experience in oncology, cancer prevention, and clinical research. Her leadership marks an important step as Mammogen advances its clinical validation efforts and explores how blood-based diagnostics can complement traditional breast imaging. Click Here to Read the Full Press Release →

Mammogen Appoints Diagnostics Industry Leader, Dr. Robert S. Epstein, to Board of Directors

13 October 2026
Mammogen announced the appointment of Robert S. Epstein, M.D., M.S., to its Board of Directors as an Independent Director. Dr. Epstein brings decades of experience in genomics, precision medicine, and oncology diagnostics, including leadership roles with Illumina, Veracyte, and Decipher Biosciences. His appointment strengthens Mammogen's leadership as the company continues advancing genTRU-breast™, its RNA-powered blood-based assay designed to support earlier breast cancer detection, through clinical validation and toward commercialization. Click Here to Read the Full Press Release →

CEO of Mammogen highlights the benefits of blood-based cancer detection

9 October 2026
Rockford News First | October 9, 2026 Rockford News First featured Mammogen CEO Elizabeth Cormier-May in a news segment discussing the growing role of blood-based testing in cancer detection. During the interview, Cormier-May explains how Mammogen is using RNA-powered technology to support earlier breast cancer detection, particularly for women with dense breast tissue. She also discusses how blood-based diagnostics could complement traditional mammography and help make cancer screening more accessible. Click Here to Watch the Full News Segment →